Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17865774 | 1.00 | NPC1 (0.39) | NPC1HSD17B10CHRM3NPSR1CHRM1 | |
| SCHEMBL19521206 | 0.95 | CHRM3 (0.41) | NPC1HSD17B10CHRM3CHRM1TP53 | |
| SCHEMBL19521203 | 0.95 | CHRM3 (0.41) | NPC1HSD17B10CHRM3CHRM1TP53 | |
| SCHEMBL19521209 | 0.95 | CHRM3 (0.41) | NPC1HSD17B10CHRM3CHRM1TP53 | |
| SCHEMBL19541283 | 0.95 | CHRM3 (0.41) | NPC1HSD17B10CHRM3CHRM1TP53 | |
| SCHEMBL17999632 | 0.89 | PIK3CD (0.35) | MMP2ADAM17ADAMTS5CYP1A2TDP1 | |
| SCHEMBL19541670 | 0.88 | ALDH1A1 (0.35) | NPC1MMP2ADAM17ADAMTS5LIPE | |
| SCHEMBL20952055 | 0.88 | ALDH1A1 (0.35) | NPC1MMP2ADAM17ADAMTS5LIPE | |
| SCHEMBL17865745 | 0.87 | MMP2 (0.33) | MMP2ADAM17ADAMTS5 | |
| SCHEMBL20153497 | 0.87 | MMP2 (0.33) | MMP2ADAM17ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057808-A1 | COMPOSITION COMPRISING BETA LACTAM FOR TREATING ALCOHOL DEPENDENCE AND ALCOHOL ASSOCIATED DISEASES OR CONDITIONS | UNIVERSITY OF TOLEDO | 2025-02-20 | — | — | US | disclosed |
| US-9975879-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975879-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975879-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | disclosed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | disclosed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | disclosed |
| EP-3036219-A2 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | Temple University Of The Commonwealth System Of Higher Education (US) | 2016-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057808-A1 | COMPOSITION COMPRISING BETA LACTAM FOR TREATING ALCOHOL DEPENDENCE AND ALCOHOL ASSOCIATED DISEASES OR CONDITIONS | ADH1A, ADH1C, SLC10A1 | NPC1 212/4885HSD17B10 158/4885CHRM3 806/4885 |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | SLC1A2, SLC7A11, SLC18A2 | NPC1 512/4885HSD17B10 735/4885CHRM3 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.